Microbiota Transplant for Children with Autism
Imagine moving from a diagnosis of “severe” autism to no longer meeting the criteria for autism spectrum disorder (ASD). The recently completed Microbiota Transplant Therapy (MTT) Phase 1 study indicates such results are possible and sustainable.
At the beginning of the study, 83% of participants were classified as “severe” on an autism diagnosis scale. At a 2 year follow up, only 17% were still “severe”, and 44% no longer met the criteria for an autism diagnosis. Most participants had significant improvements in core autism symptoms and gastrointestinal problems.
View Full ArticleYou need to login or register to bookmark/favorite this content.